Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression [3]

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 538-

  Amsellem Ouazana, D ^a   Beuzeboc, P ^a   Peyromaure, M ^a   Viellefond, A ^a   Zerbib, M ^a   Debre, B ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PACLITAXEL; TRASTUZUMAB;

ADULT; AREA UNDER THE CURVE; BLADDER CANCER; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER REGRESSION; CANCER RESISTANCE; CASE REPORT; CAUSE OF DEATH; CYSTECTOMY; DRUG EFFICACY; DRUG RESPONSE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LIVER METASTASIS; LUNG METASTASIS; MALE; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS;

EID: 1842450734     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh112     Document Type: Letter

References (5)

1. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
2. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001; 12 (Suppl 1): S81-S87.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001; 344: 783-792.
4. Gandour-Edwards R, Lara PN Jr, Folkins AK et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002; 95: 1009-1015.
5. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003; 4: 489-497.